银屑病关节炎患者类风湿因子阳性的临床结局
本研究基于大型银屑病关节炎队列,纳入1996年后入组患者,每年检测类风湿因子(RF)。1074例中RF阳性173例(16.1%),基线阳性55例(5.1%)。RF阳性与达到最小疾病活动度(MDA)的 odds 降低相关(多变量 OR 0.53,95%CI 0.37-0.77),并与生物制剂改善病情抗风湿药(bDMARD)停药 odds 增加相关(多变量 OR 2.65,95%CI 1.34-5.24;新发阳性 OR 2.78,95%CI 1.57-4.92)。
要点
- 银屑病关节炎队列中RF阳性率16.1%,基线阳性率5.1%。
- RF阳性与达到MDA的 odds 降低独立相关(OR 0.53)。
- RF阳性与bDMARD停药 odds 增加相关(OR 2.65-2.78)。
核心结论
- RF阳性与银屑病关节炎患者达到MDA的 odds 降低及bDMARD停药 odds 增加相关。
研究设计与样本
- 基于大型银屑病关节炎队列,纳入1996年后入组患者,每年检测RF,采用广义估计方程进行单变量和多变量分析。
主要发现
- 1074例患者中RF阳性173例(16.1%),基线阳性55例(5.1%)。
- RF阳性与达到MDA的 odds 降低显著相关(多变量 OR 0.53,95%CI 0.37-0.77),主要由患者疼痛、患者总体评估和躯体功能较差驱动,尤其在bDMARD亚组。
- 曾阳性及新发RF阳性均与bDMARD停药 odds 增加相关(多变量 OR 2.65,95%CI 1.34-5.24;OR 2.78,95%CI 1.57-4.92),独立于关节和皮肤疾病活动度。
关键数值与推荐
- MDA达成:RF阳性 vs 阴性多变量 OR 0.53(95%CI 0.37-0.77)。
- bDMARD停药:曾RF阳性多变量 OR 2.65(95%CI 1.34-5.24);新发RF阳性多变量 OR 2.78(95%CI 1.57-4.92)。
临床怎么用
- 在银屑病关节炎患者中检测RF可能有助于识别MDA达成率较低和bDMARD停药风险较高的亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The clinical and immunologic significance of rheumatoid factors (RF) in psoriatic arthritis (PsA) remains unclear. We aimed to determine the frequency and impact of RF positivity on clinical outcomes and biologic (b) disease-modifying anti-rheumatic drug (DMARD) discontinuation in PsA. METHODS: Patients enrolled after 1996 from a large PsA cohort were included for this study. RF was tested annually and was defined as ever positive or newly positive (excluding those positive at enrolment). Associations of RF with clinical outcomes, including achievement of minimal disease activity (MDA), components of MDA and bDMARD discontinuation, were assessed using univariable (UV) and multivariable (MV) generalized estimating equations. RESULTS: Among 1074 patients, RF positivity was observed in 173 (16.1%) overall, including 55 (5.1%) who were positive at baseline. RF positivity was significantly associated with reduced odds for achievement of MDA (MV, OR 0.53, 95% CI 0.37-0.77), driven by worse patient pain, patient global and physical function, particularly in the bDMARD subgroup. These associations persisted in the bDMARDs subgroup when analyses were restricted to new RF positivity. Additionally, ever and new RF positivity was associated with increased odds for bDMARD discontinuation (MV, OR 2.65, 95% CI 1.34-5.24 and 2.78, 95% CI 1.57-4.92, respectively) independent of joint and skin disease activity. CONCLUSION: RF was observed in 16.1% of the cohort, with 5.1% being positive at baseline. RF positivity was associated with lower odds for achievement of MDA and with bDMARD discontinuation.
引用
- Mehta P, Kharouf F, Carrizo Abarza V, et al. Clinical outcomes in psoriatic arthritis patients with rheumatoid factor positivity. Rheumatology (Oxford). 2026. PMID: 42033784. doi:10.1093/rheumatology/keag240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。